LabGenius raises $10M to use AI for protein drug discovery

LabGenius, a London-based startup applying AI and “robotic automation” to protein drug discovery, has raised $10 million in Series A funding.
The round is led by Lux Capitaland Obvious Ventures,with participation from Felicis Ventures, Inovia Capital, Air Street Capital and existing investors. Also investing is Recursion Pharmaceuticals’ founder and CEO Chris Gibson, as well as Inovia Capital General Partner Patrick Pichette, who was formerly Google’s CFO.
Lux Capital&rsq